What question did this study set out to answer?

To evaluate the antitumor efficacy, DNA-binding affinity, and toxicity profile of the rationally designed ellipticine derivative 9-hydroxyellipticine.

December 1, 1974Proceedings of the National Academy of SciencesOpen Access

A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational Design of Anticancerous Drugs in the Series of DNA Intercalating Drugs

View Full Paper

Ask AI

Bookmark

Authors

JPJean‐Bernard Le PecqSiemens (Hungary)NNguyen‐Dat‐XuongCentre National de la Recherche Scientifique CGCharles GosseInstitut Gustave Roussy

Discussion

Member takes

Implication

Preclinical evaluation demonstrates high antitumoral activity and low toxicity of 9-hydroxyellipticine in murine leukemia, suggesting a rational framework for designing DNA intercalating drugs.

Key Points

To evaluate the antitumor efficacy, DNA-binding affinity, and toxicity profile of the rationally designed ellipticine derivative 9-hydroxyellipticine.
Synthesized 9-hydroxyellipticine within the ellipticine series specifically engineered for high DNA intercalation affinity.
Assessed pharmacological reactivity, therapeutic toxicity, and antileukemic efficacy in L1210 murine leukemia models.
9-Hydroxyellipticine exhibited high DNA binding affinity alongside strong antitumoral activity against L1210 leukemia.
Therapeutic doses produced effective antileukemic activity without exhibiting drug-related toxicity.

Cite This Study

Pecq et al. (1974) studied this question.

synapsesocial.com/papers/6a881724010a27dee476f6bb https://doi.org/10.1073/pnas.71.12.5078

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation demonstrates high antitumoral activity and low toxicity of 9-hydroxyellipticine in murine leukemia, suggesting a rational framework for designing DNA intercalating drugs.

A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational Design of Anticancerous Drugs in the Series of DNA Intercalating Drugs

Discussion

Member takes

Implication

Key Points

Cite This Study

A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational Design of Anticancerous Drugs in the Series of DNA Intercalating Drugs

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider